Depletion of pDCs may benefit these malignancies, thus, GL-C2-C4 and GL-C2-C5 may prove effective in this capacity; however, it should be pointed out that the PMDC05 cell line used in this study is itself derived from a pDC lymphoma so further investigations using purified primary pDCs from subjects with AML is warranted to evaluate the pDC-depleting capacity in this context. The gene discussed is PDC; the disease is acute myeloid leukemia.